NANOBODY® Molecule, a Giga Medical Tool in Nanodimensions
Open Access
- 25 August 2023
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (17) , 13229
Abstract
Although antibodies remain the most widely used tool for biomedical research, antibody technology is not flawless. Innovative alternatives, such as Nanobody® molecules, were developed to address the shortcomings of conventional antibodies. Nanobody® molecules are antigen-binding variable-domain fragments derived from the heavy-chain-only antibodies of camelids (VHH) and combine the advantageous properties of small molecules and monoclonal antibodies. Nanobody® molecules present a small size (~15 kDa, 4 nm long and 2.5 nm wide), high solubility, stability, specificity, and affinity, ease of cloning, and thermal and chemical resistance. Recombinant production in microorganisms is cost-effective, and VHH are also building blocks for multidomain constructs. These unique features led to numerous applications in fundamental research, diagnostics, and therapy. Nanobody® molecules are employed as biomarker probes and, when fused to radioisotopes or fluorophores, represent ideal non-invasive in vivo imaging agents. They can be used as neutralizing agents, receptor-ligand antagonists, or in targeted vehicle-based drug therapy. As early as 2018, the first Nanobody®, Cablivi (caplacizumab), a single-domain antibody (sdAb) drug developed by French pharmaceutical giant Sanofi for the treatment of adult patients with acquired thrombocytopenic purpura (aTTP), was launched. Nanobody® compounds are ideal tools for further development in clinics for diagnostic and therapeutic purposes.Keywords
Funding Information
- French Institute of Cancer (InCa-PLBio R19004AP, TAUS23380, ANR-15-IDEX-01)
- French charity: “La Ligue Contre le Cancer” (InCa-PLBio R19004AP, TAUS23380, ANR-15-IDEX-01)
- National Research Agency (ANR) (InCa-PLBio R19004AP, TAUS23380, ANR-15-IDEX-01)
This publication has 147 references indexed in Scilit:
- In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) FragmentsAntibodies, 2013
- Engineered Single-Domain Antibodies with High Protease Resistance and Thermal StabilityPLOS ONE, 2011
- Therapeutic antibodies: successes, limitations and hopes for the futureBritish Journal of Pharmacology, 2009
- Development of ELISAs for the measurement of IgM and IgG subclasses in sera from llamas (Lama glama) and assessment of the humoral immune response against different antigensVeterinary Immunology and Immunopathology, 2008
- Properties, production, and applications of camelid single-domain antibody fragmentsApplied Microbiology and Biotechnology, 2007
- Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs)Journal of Immunological Methods, 2007
- Generation of heavy-chain-only antibodies in miceProceedings of the National Academy of Sciences, 2006
- Formatted anti–tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen‐induced arthritisArthritis & Rheumatism, 2006
- Camel heavy‐chain antibodies: diverse germline VHH and specific mechanisms enlarge the antigen‐binding repertoireThe EMBO Journal, 2000
- Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coliNature, 1989